ナビキシモルス (Japanese Wikipedia)

Analysis of information sources in references of the Wikipedia article "ナビキシモルス" in Japanese language version.

refsWebsite

Global rank Japanese rank

12nih.gov

4^th place

24^th place

7doi.org

2^nd place

6^th place

2gwpharm.com

low place

1ama-assn.org

3,257^th place

6,629^th place

1nature.com

234^th place

363^rd place

1telegraph.co.uk

30^th place

177^th place

1forbesjapan.com

5,753^rd place

343^rd place

1theargus.co.uk

2,780^th place

2,381^st place

1thisislincolnshire.co.uk

low place

1drugdevelopment-technology.com

low place

1reuters.com

49^th place

67^th place

ama-assn.org

United States Adopted Names Coincil: Statement on a nonproprietary name

doi.org

Pain, Stephanie (2015). “A potted history”. Nature 525 (7570): S10–S11. doi:10.1038/525S10a. PMID 26398731.
Lakhan, Shaheen E; Rowland, Marie (2009). “Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review”. BMC Neurol 9: 59. doi:10.1186/1471-2377-9-59. PMC 2793241. PMID 19961570.
Zettl, Uwe K.; Rommer, Paulus; Hipp, Petra; et al. (2016). “Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis”. Therapeutic Advances in Neurological Disorders 9 (1): 9–30. doi:10.1177/1756285615612659. PMC 4710104. PMID 26788128.
Wade D, Makela P, Robson P, House H, Bateman C (2004). “Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients”. Mult Scler 10 (4): 434–41. doi:10.1191/1352458504ms1082oa. PMID 15327042.
Wade D, Makela P, House H, Bateman C, Robson P (2006). “Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis”. Mult Scler 12 (5): 639–45. doi:10.1177/1352458505070618. PMID 17086911.
Wade D, Robson P, House H, Makela P, Aram J (2003). “A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms”. Clin Rehabil 17 (1): 21–9. doi:10.1191/0269215503cr581oa. PMID 12617376.
Nutt, David (2015). “Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research”. PLOS Biology 13 (1): e1002047. doi:10.1371/journal.pbio.1002047. PMC 4307971. PMID 25625189.

drugdevelopment-technology.com

“Sativex - Investigational Cannabis-Based Treatment for Pain and Multiple Sclerosis Drug Development Technology”. www.drugdevelopment-technology.com. 2008年8月8日閲覧。

forbesjapan.com

Borchardt, Debra (2016年12月9日). “英製薬会社、臨床試験結果に自信も「トランプ大統領」に不安”. フォーブス日本版 2017年9月1日閲覧。

gwpharm.com

GW Pharmaceuticals. "Multiple Sclerosis". Accessed 24 July 2011.
GW Pharmaceuticals. "Cancer Pain" Accessed 24 July 2011.

nature.com

Pain, Stephanie (2015). “A potted history”. Nature 525 (7570): S10–S11. doi:10.1038/525S10a. PMID 26398731.

nih.gov

pubmed.ncbi.nlm.nih.gov

Pain, Stephanie (2015). “A potted history”. Nature 525 (7570): S10–S11. doi:10.1038/525S10a. PMID 26398731.
Lakhan, Shaheen E; Rowland, Marie (2009). “Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review”. BMC Neurol 9: 59. doi:10.1186/1471-2377-9-59. PMC 2793241. PMID 19961570.
Zettl, Uwe K.; Rommer, Paulus; Hipp, Petra; et al. (2016). “Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis”. Therapeutic Advances in Neurological Disorders 9 (1): 9–30. doi:10.1177/1756285615612659. PMC 4710104. PMID 26788128.
Wade D, Makela P, Robson P, House H, Bateman C (2004). “Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients”. Mult Scler 10 (4): 434–41. doi:10.1191/1352458504ms1082oa. PMID 15327042.
Wade D, Makela P, House H, Bateman C, Robson P (2006). “Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis”. Mult Scler 12 (5): 639–45. doi:10.1177/1352458505070618. PMID 17086911.
Wade D, Robson P, House H, Makela P, Aram J (2003). “A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms”. Clin Rehabil 17 (1): 21–9. doi:10.1191/0269215503cr581oa. PMID 12617376.
Nutt, David (2015). “Illegal Drugs Laws: Clearing a 50-Year-Old Obstacle to Research”. PLOS Biology 13 (1): e1002047. doi:10.1371/journal.pbio.1002047. PMC 4307971. PMID 25625189.

pmc.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

Lakhan, Shaheen E; Rowland, Marie (2009). “Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review”. BMC Neurol 9: 59. doi:10.1186/1471-2377-9-59. PMC 2793241. PMID 19961570.
Zettl, Uwe K.; Rommer, Paulus; Hipp, Petra; et al. (2016). “Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosis”. Therapeutic Advances in Neurological Disorders 9 (1): 9–30. doi:10.1177/1756285615612659. PMC 4710104. PMID 26788128.

reuters.com

jp.reuters.com

“英ＧＭファーマ、がん疼痛治療剤が試験で十分な効果示さず”. 2015年1月8日閲覧。

telegraph.co.uk

“GW signs Sativex cannabis-based drug deal with Novartis”. The Telegraph. (11 April 2011) 12 July 2012閲覧。

theargus.co.uk

Ryan, Siobhan (4 June 2011). “Sussex MS sufferers call for drug funding”. Argus (Sussex,UK) 8 June 2011閲覧。

thisislincolnshire.co.uk

“Sativex rejected by healthcare provider”. Lincolnshire (20 June 2011). 20 June 2011閲覧。